title: Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies.
abstract: BACKGROUND
  GW406381 is an investigational, highly selective cyclooxygenase-2 (COX-2) inhibitor that is effective in animal models of central sensitization and of inflammatory pain.
  
  
  OBJECTIVE
  To examine dose response for efficacy and safety of GW406381 in adults with osteoarthritis (OA) of the knee.
  
  
  METHODS
  Two randomized, double-blind, placebo- and positive-control studies: Study A, a 6-week nonflare design; Study B, a 12-week flare design.
  
  
  METHODS
  649 patients entered Study A; 1331 patients entered Study B.
  
  
  METHODS
  
  
  
  METHODS
  GW406381 10, 20, 35, or 50 mg, celecoxib 200 mg, or placebo. Study B: GW406381 1, 5, 10, 25, or 50 mg, celecoxib 200 mg, or placebo.
  
  
  METHODS
  Study A, co-primary endpoints were change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore and WOMAC question 1. Study B co-primary endpoints were change from baseline in WOMAC pain and function subscores and Patient Global Assessment of Arthritis Condition. A closed hierarchical test procedure was prespecified.
  
  
  RESULTS
  Study A demonstrated that GW406381 50 mg was superior to placebo on WOMAC pain subscore (mean difference from placebo -6.9 mm; P= .012). No clear dose response was observed, and the results with celecoxib were no different from those of placebo. In Study B, no dose of GW406381 was superior to placebo on the co-primary endpoints. Celecoxib was superior to placebo on all co-primary endpoints. Dose-related blood pressure and renovascular effects were seen with GW406381.
  
  
  CONCLUSIONS
  Overall, clinically meaningful efficacy in pain related to OA of the knee was not demonstrated for GW406381 despite its peripheral and central sites of action.
authors.affiliation: Clinical Development, GlaxoSmithKline, Harlow, United Kingdom. diane.j.boswell@gsk.com
authors.forename: Diane J
authors.initials: DJ
authors.lastname: Boswell
authors.forename: Keld
authors.initials: K
authors.lastname: Ostergaard
authors.forename: Richard S
authors.initials: RS
authors.lastname: Philipson
authors.forename: Rachel A
authors.initials: RA
authors.lastname: Hodge
authors.forename: David
authors.initials: D
authors.lastname: Blum
authors.forename: Judith C
authors.initials: JC
authors.lastname: Brown
authors.forename: Steve N
authors.initials: SN
authors.lastname: Quessy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000175:diagnosis* / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D011724:Pyridazines / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; C469818:GW406381X; D011720:Pyrazoles; D011724:Pyridazines